Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Anti-Inflammatory Biologics Industry?

The market size of anti-inflammatory biologics has seen a robust growth in the past few years. Predictions suggest that it will rise from $108.11 billion in 2024 to $118.02 billion in 2025, with a compound annual growth rate (CAGR) of 9.2%. The growth experienced in the historic period is due to factors such as a higher prevalence of arthritis, increased understanding of autoimmune disorders, the introduction of new biologic products, improved healthcare infrastructure, and a rise in regulatory validation.

Explosive expansion is projected for the anti-inflammatory biologics market in the upcoming years, with the valuation set to reach $166.28 billion by 2029, boasting a compound annual growth rate (CAGR) of 9.0%. This projected growth within the forecast duration ties to the increasing preference for biologics, escalating demand for specific treatments, growing inclination towards long-term symptom relief, expanded utilization of biomarkers for disease tracking, and surging appetite for bespoke medication. The forecast span is also expected to see notable trends such as progress in the creation of biologic drugs, emergence of oral biologics for inflammation, the rise of tech-based drug delivery systems, growth in biosimilar development, and enhancement in diagnostic tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

What Forces Are Driving The Growth Of The Anti-Inflammatory Biologics Industry?

The escalating occurrence of arthritis is anticipated to boost the expansion of the anti-inflammatory biologics market in the future. Arthritis signifies inflammation or swelling in one or more joints, which results in pain, rigidity, and limited movement, often deteriorating with age. The surging occurrence of arthritis is chiefly owing to escalating obesity rates, since excessive body weight exerts added stress on joints, leading to inflammation and joint degeneration. Anti-inflammatory biologics are beneficial for arthritis by aiming at precise elements of the immune system to lessen inflammation, decelerate joint damage, alleviate symptoms, and improve physical capability and quality of life for individuals with moderate to severe arthritis. For example, in March 2023, the Office for Health Improvement and Disparities, a government department based in the UK, reported that in 2022, 17.6% of individuals aged 16 or older had a long-term MSK condition such as arthritis or a persistent back or joint issue, an increase from 17.0% in 2021. As such, the escalating occurrence of arthritis is propelling the expansion of the anti-inflammatory biologics market.

What Is The Overview Of Market Segmentation In The Anti-Inflammatory Biologics Industry?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics

What Future Market Trends Are Projected For The Anti-Inflammatory Biologics Industry?

Leading corporations in the anti-inflammatory biologics market are concentrating on the creation of advanced solutions, such as interleukin-6 (IL-6) receptor antagonists, to more precisely target chronic inflammation diseases and minimize adverse effects. Interleukin-6 (IL-6) receptor antagonists are a type of biologic medicine designed to obstruct the IL-6 receptor, thereby reducing inflammation and immune response for ailments like rheumatoid arthritis. For example, in February 2023, the US-based biotech firm, Regeneron Pharmaceuticals Inc., obtained the approval from the US Food and Drug Administration (FDA) for Kevzara – it’s the first and exclusive biologic treatment intended for those suffering from polymyalgia rheumatica (PMR) who are not adequately reacting to corticosteroids. Kevzara is a fully human monoclonal antibody that obstructs the IL-6 receptor and is effective in reducing inflammation related to PMR, a disease causing muscle pain and rigidity, primarily in seniors. Contrary to conventional steroids, which pose risks such as osteoporosis and diabetes with long-term use, Kevzara offers a more specific, steroid-saving method that contributes to improved patient results and superior long-term safety.

Who Are The Primary Players Operating Across The Global Anti-Inflammatory Biologics Market?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Which Region Offers The Most Growth Potential For The Anti-Inflammatory Biologics Market Through 2029?

North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model